Lumakras
Payments companies reported to CMS as associated with Lumakras. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lumakras, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lumakras
These are the largest totals companies reported as associated with Lumakras. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Melissa Johnson | Nashville, TN | Medical Oncology | $59,154.61 |
| David Waterhouse | Cincinnati, OH | Hematology & Oncology | $55,864.18 |
| Hatim Husain | San Diego, CA | Internal Medicine | $45,490.02 |
| Leroy Keiser | Santa Rosa, CA | Hematology & Oncology | $44,038.71 |
| Joshua Strauss | Springfield, NJ | Hematology & Oncology | $42,984.03 |
| Tarek Mekhail | Orlando, FL | Hematology & Oncology | $34,194.70 |
| Beth Sandy | Philadelphia, PA | Adult Health (Nurse Practitioner) | $30,021.36 |
| Ferdinandos Skoulidis | Houston, TX | Medical Oncology | $26,485.23 |
| Aneel Chowdhary | Huntington, WV | Medical Oncology | $22,106.94 |
| Grace Dy | Buffalo, NY | Hematology & Oncology | $20,657.50 |
Prescribed Lumakras?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.